In the pharmaceutical industry, Leflunomide is a powerful Disease-Modifying Antirheumatic Drug (DMARD) used primarily for Rheumatoid Arthritis (RA) and Psoriatic Arthritis. As a pharmacist and manufacturer, I view this molecule as an “Immunomodulatory Sentinel”: it selectively inhibits the proliferation of overactive lymphocytes, but its long half-life ($t_{1/2} \approx 2$ weeks) means its side effects require careful, long-term monitoring.
At your WHO-GMP facility in Mumbai, where you likely produce the 10 mg and 20 mg tablets, emphasizing the “loading dose” vs. “maintenance dose” safety profile is a key technical value-add for your rheumatology portfolio.
1. Primary & Common Side Effects
The side effects of Leflunomide are often dose-related and frequently appear during the first 3 to 6 months of therapy.
| Category | Side Effect | Technical Rationale |
| Gastrointestinal | Diarrhea & Nausea | The most common complaint. It occurs due to the drug’s impact on the rapidly dividing cells of the GI tract. |
| Dermatological | Hair Thinning (Alopecia) | Usually reversible upon dose reduction or discontinuation; affects the hair follicle growth cycle. |
| Cardiovascular | Hypertension | Leflunomide can cause a significant increase in blood pressure. Baseline and regular monitoring are mandatory. |
| General | Skin Rash & Pruritus | Mild allergic reactions are common, though severe reactions (like Stevens-Johnson Syndrome) are rare. |
2. Serious Clinical Warnings
As a manufacturer, these are the high-priority risks that must be clearly detailed in your technical dossiers and product inserts.
Hepatotoxicity (Liver Injury)
Leflunomide can cause a dangerous elevation in liver enzymes.
Protocol: Baseline ALT (SGPT) levels must be taken. Monitoring should occur every month for the first six months, then every 6–8 weeks thereafter.
Risk Factor: Using Leflunomide concurrently with other hepatotoxic drugs (like Methotrexate) significantly increases this risk.
Teratogenicity (Pregnancy Risk)
Leflunomide is strictly contraindicated in pregnancy (Category X).
Persistence: Because the active metabolite (teriflunomide) stays in the body for up to 2 years, women of childbearing age must undergo a “Drug Elimination Procedure” using Cholestyramine before attempting to conceive.
Infection Risk
By suppressing the immune system, it can increase susceptibility to infections and may reactivate latent tuberculosis (TB).
3. Mechanism: Pyrimidine Synthesis Inhibition
Leflunomide is a prodrug that is rapidly converted into its active metabolite, A77 1726.
Enzyme Blockade: It inhibits Dihydroorotate Dehydrogenase (DHODH), an enzyme essential for de novo pyrimidine synthesis.
Lymphocyte Arrest: Activated T-cells and B-cells depend on this pathway to multiply. By cutting off their supply of pyrimidines, the drug “starves” the autoimmune response.
Selectivity: Most other body cells can use a “salvage pathway” to get pyrimidines, which is why the drug specifically targets the overactive immune cells.
The Pharmacist’s “Technical Protocol”
The “Washout” Strategy: Because the drug lasts so long in the system, if a patient has a severe reaction, you cannot just stop the pill. You must administer Cholestyramine 8g TID for 11 days to physically pull the drug out of the enterohepatic circulation.
Alcohol Restriction: To protect the liver, patients should be advised to limit or completely avoid alcohol consumption while on therapy.
CBC Monitoring: Although rare, Leflunomide can cause bone marrow suppression; periodic Complete Blood Counts are recommended.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Bioequivalence” USP: For B2B export, highlight your Dissolution Profiles comparing your tablets to the innovator (Arava). Since it has a long half-life, demonstrating consistent release is critical.
Stability for Export: Leflunomide is sensitive to moisture. Utilizing Alu-Alu blister packaging is essential for maintaining a 36-month shelf life in Zone IVb tropical regions.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers with updated safety data to support your firm’s registration in international orthopedic and rheumatology tenders.